Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors

NCT05219578 is registered in ClinicalTrials.gov with Rubius Therapeutics as lead sponsor.

NCT NCT05219578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Rubius Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
January 12, 2022
Completion date
November 30, 2022
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, head and neck squamous cell carcinoma, non small cell lung cancer, tnbc - triple-negative breast cancer, urothelial carcinoma